Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers June 24, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - June 24, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/25/17 - "Method and Pharmaceutical Composition for Inhibiting Pi3k/Akt/Mtor Signaling Pathway" in Patent Application Approval Process (USPTO 20170119747)
By a News Reporter-Staff News Editor at Women's Health Weekly A patent application by the inventors Duan, Lei; Levenson, Victor; Ying, GuoGuang, filed on November 22, 2016, was made available online on May 11, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assign
5/25/17 - Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Orphan Drug Designation for Abeona s EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa, including recessive dystrophic.
5/25/17 - Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A [Sport360]
Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Actimab-A has been granted orphan designation in the European Union by the European Medicines Agency. Actimab-A is intended to be used, upon approval, in patients newly...
5/25/17 - Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors
Ms. Mikail brings both a broad legal skillset and substantial business development experience in the pharmaceutical industry, stated Stefano Buono, Chief Executive Officer of AAA. Her expertise in these areas will augment the current board composition, as we continue to build a global enterprise and advance the development and commercializ
5/25/17 - AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI
LONDON- Today's Daily Dose brings you news about Aerie Pharma's positive efficacy results from phase III study of its glaucoma drug candidate Roclatan; Alnylam's public offering and FDA panel's support for approval of Puma's breast cancer drug Neratinib. Shares of Aerie Pharmaceuticals Inc. climbed more than 27% in extended trading on Wednesday,...
5/25/17 - AG Paxton Announces $2 Million Settlement Payment to Baylor College of Medicine for Pediatric Neurological Research
Attorney General Ken Paxton today announced that the Baylor College of Medicine will receive $2 million from a settlement reached by Texas with Questcor Pharmaceuticals, Inc. Baylor College of Medicine will use the $2 million for funding related to innovative pediatric neurological research projects. In January, Texas, the Federal Trade Commission
5/25/17 - AG Paxton, 42 States Reach $33 Million Settlement with Johnson & Johnson Regarding Quality of Over-Counter Drugs
Attorney General Ken Paxton today announced that Texas will receive more than $2.2 million in a $33 million, 43- state settlement with pharmaceutical company Johnson& Johnson. From 2009 to 2011, alleged quality control lapses by McNeil-PPC, Inc., a wholly-owned subsidiary of Johnson& Johnson, resulted in recalls of many over-the-counter drugs for a
5/25/17 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507
5/25/17 - Agios Pharmaceuticals Inc Stake Boosted by Canada Pension Plan Investment Board [Emirates News Agency (WAM) (United Arab Emirates)]
Canada Pension Plan Investment Board raised its stake in Agios Pharmaceuticals Inc by 152.1% during the first quarter, according to its most recent 13 F filing with the SEC. Canada Pension Plan Investment Board owned about 0.07% of Agios Pharmaceuticals worth $1,781,000 as of its most recent SEC filing. Wells Fargo& Company MN boosted its position
5/25/17 - Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., today announced the publication in The New England Journal of Medicine of key preclinical findings with angiopoietin-like 3- targeting drugs and Phase 1/ 2 clinical study results with AKCEA-ANGPTL3-L Rx. Furthermore, in preclinical studies, we have shown that targeting
5/25/17 - Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer
Akebia Therapeutics, Inc., a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor, today announced the appointment of Rita Jain, M.D. as Senior Vice President and Chief Medical Officer. Dr. Jain succeeds Brad Maroni, M.D. who will remain at Akebia as a m
5/25/17 - Albireo Prices $45.1 Million Public Offering of Common Stock [Emirates News Agency (WAM) (United Arab Emirates)]
-Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 2,200,000 shares of its common stock at a price to the public of $20.50 per share. The offering will be made only by means of a written prospect
5/25/17 - Ammonett Pharma Receives Notice of Allowance of U.S. Patent for Oratrope? Related to Detecting and Treating Growth Hormone Deficiency
Ammonett Pharma LLC, a privately-held biotechnology company developing a novel, daily, orally-administered mini-pill Growth Hormone secretagogue, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Patent Application No: 15/ 271,542, entitled DETECTING AND TREATING GROWTH HORMONE DEFICIENCY
5/25/17 - APR Applied Pharma Research at the 9th ChinaBio Partnering Forum: Bringing Swiss Made Innovations and Science Driven Technologies to Strengthen Its Presence in the Chinese Market
BALERNA, Switzerland APR Applied Pharma Research s.a., the Swiss independent developer of science driven and patent protected healthcare products, will participate to the 9 th ChinaBio Partnering Forum, which will be held in Zhuhai, China, May 31 st- June 1 st, 2017, presenting company innovations and science driven technologies in order to
5/25/17 - Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics
LONDON, 25 May, 2017: Arix Bioscience plc, a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million. Arix Bioscience co-led the financing round with New Leaf Venture Partners, and additional new investo
5/25/17 - Bharat Book Bureau: Global Depth Filtration Market by Media
The global depth filtration market is projected to reach USD 2.96 billion by 2022 from USD 1.70 billion in 2017, at a CAGR of 11.7% from 2017 to 2022. Increasing demand for biopharmaceuticals and increasing R&D expenditure in the biopharmaceutical industry are the major factors driving the growth of the global depth filtration market.
5/25/17 - BIOCRYST PHARMACEUTICALS INC FILES (8-K) Disclosing Regulation FD Disclosure, Financial Statements and Exhibits
On May 25, 2017, BioCryst Pharmaceuticals, Inc. announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema. On May 25, 2017, the Company issued a news release announcing the events described in this Item 7.01. Some of the factors that could affect the forward-looking statements contained herein in
5/25/17 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure Item 7.01. Regulation FD Disclosure. On May 25, 2017, BioCryst Pharmaceuticals, Inc. (the Company) announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial designed to
5/25/17 - BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
BioCryst Pharmaceuticals, Inc. today announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema. APeX-1 is a 3- part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once-daily BCX7353 for 28 days, as a preve
5/25/17 - Blake Insomnia Therapeutics Inc. Announces Appointment of Kyle Sarwal and Ajit Johal to its Board of Directors
Blake Insomnia Therapeutics Inc. a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal to its Board of Directors.. Mr. Sarwal is a director and business development expert for SAJO Consulting, a company with management, research, scientific, and regulatory expertise. Ajit brings to Blake I
5/25/17 - Blog Coverage Merck's KEYTRUDA Becomes First Cancer Drug to be Approved by FDA Based on a Common Biomarker Instead of the Location of the Tumor
Upcoming AWS Coverage on Retrophin Post-Earnings Results. LONDON, UK/ ACCESSWIRE/ May 25, 2017/ Active Wall St. blog coverage looks at the headline from Merck& Co., Inc. as the Company announced that the US Food and Drug Administration has granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature.
5/25/17 - Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China [Mid-East.Info]
First phase investment of more than ?70 million The facility is designed to operate 2000 L scale single-use bioreactors and fill/finish capabilities It is the first and only biopharmaceutical manufacturing site established by a multinational active pharmaceutical company in China Dubai, United Arab Emirates: Today, Boehringer Ingelheim...
5/25/17 - Cancer resistance firm TP Therapeutics reaps $45M in third round [Arab Finance (Egypt)]
The company was co-founded in 2013 by ex- Pfizer scientist Jean Cui, Ph.D., who was behind the development of the drugmaker`s $560 million drug Xalkori and is hoping to repeat that success with TP`s lead candidate, TPX-0005. Proceeds from the third-round financing, co-led by Lilly Asia Ventures, OrbiMed Advisors, and S.R. If TP`s prediction pans ou
5/25/17 - Catalent to Host Spray Drying Technology Symposium to Highlight Solubility and Bioavailability Solutions
"Pre-formulation Studies to Ensure Successful Development of Spray-Dried Dispersions," P.Y. Chen, Director of Early Development, Catalent; " Spray-Dried Dispersion Formulation Development for Early Phase Clinical Studies," Nathan Barksdale, Senior Scientist, Catalent; " Spray-Dried Dispersion Process Development," Jon Scrafford, Manager of Process.
5/25/17 - Clinical Laboratory Test Market Growth, Trends, Analysis and Forecast to 2017-2022
Key Players: bbott Laboratories, ARUP Laboratories, Bio-Reference Laboratories, Bioscientia Healthcare, Charles River Laboratories, Clarient Inc, Covance Inc, Genoptix Medical Lab, Genzyme Corp " Market Research Future PUNE, MAHARASHTRA, INDIA, May 25, 2017/ Market Scenario: Clinical laboratories are the diagnostic laboratorie
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement